PHARMASEAL, a provider of clinical trial management and governance solutions, announces a second major release of its Engility CTMS platform. New features include site monitoring, issue management, and global access management.
With a focus on configurability and collaboration, the Engility CTMS monitoring module provides a workspace to manage all monitoring visits (onsite/remote/telephone) via an intuitive interface to support working in the system.
Commenting on the enhanced platform, Daljit Cheema, CEO and Founder of PHARMASEAL said: “Engility CTMS is a SaaS cloud platform built with agility at its core and engineered to evolve. PHARMASEALS’ collective passion for continuous innovation leads to capabilities, such as the monitoring module, so that biopharmaceutical sponsors and medical device companies of all sizes can proactively and collaboratively adopt an innovative approach.”
Flexible and scalable in order to meet the needs of all organisations, Engility CTMS enables data driven decision-making.
Further information can be found at www.pharmaseal.co
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.